2nd UPDATE: EU Reviewing Biogen, Elan's Tysabri; Cites PML
Oct 23, 2009
By Thomas Gryta
Of DOW JONES NEWSWIRES
NEW YORK -(Dow Jones)- A European panel has started a review of controversial Multiple Sclerosis drug Tysabri, sold by Biogen Idec Inc. (BIIB) and Elan PLC ( ELN), citing a much higher number of rare brain infections than previously disclosed.
In a statement, the European Medicines Agency's Committee for Medicinal Products for Human Use, commonly called CHMP, reported that there are 23 cases of progressive multifocal leukoencephalopathy, or PML, since the drug's launch. Previously, there had only been 13 confirmed cases of the infection since the drug re-entered the market in 2006, following an 18-month removal that was prompted by a link to three previous cases of PML.
Read also the Bloomberg report found here
===================================
Please remain up to date with Multiple Sclerosis news stories when registered with MS Views and News, by clicking here to complete a short registration form. - thank you
=============================================
0 comments:
Post a Comment